L.Esserman Taste for the Cure P.Walter Childrens Cancer septembeard

UCSF Helen Diller Family Comprehensive Cancer Center
member announcement for 9/15/2014
[ view online | correct or unsubscribe ]

News | Upcoming events | Funding Opps | Resources


American Association for Cancer Research to Release New Cancer Progress Report Tomorrow, Sept. 16
Report will be discussed during press teleconference and ABC News Twitter Chat

Press Teleconference, 10 a.m. ET (7 am PT)
The AACR will host a press teleconference summarizing the findings of the Cancer Progress Report. To join the teleconference, use the following dial-in information:
1-866-297-6395 (U.S. toll free)
1-847-944-7317 (U.S. toll)
Confirmation Number: 37970987

>Click here for Twitter Chat 101 from AACR
ABC News Twitter Chat, 1:00 p.m. ET (10 am PT)
The AACR will join an ABC News Twitter chat, "Report Card on Cancer," moderated by ABC News Medical Editor Richard Besser, MD.

More than 45 cancer centers from across the country have agreed to participate as well.
Follow the conversation on Twitter and join in: #abcDrBchat. Follow the AACR on Twitter: @AACR.

L.EssermanWall Street Journal, Sept 14 Featuring Dr. Laura Esserman
The surge of cancer screening in the U.S. has increased the detection of precancerous lesions that are often low-risk. Some experts now argue that cancer is being overdiagnosed.

HDFCCC In the News From UCSF.edu

Childrens CancerParents Persuade Calif. Senate to Shed Light on Children's Cancer
September 14, 2014

UCSF San Francisco Celebrates 3 New Hospitals With Stars, Lights and Action
September 8, 2014

Join Septembeard and TEAM UCSF!Join Septembeard and TEAM UCSF!
September 1, 2014

HDFCCC viewers can still view TEDMED2014 on demand until Sept 16.
Login to TEDMEDLive.org with AFFILIATE ID: L52257

Featured events

HDFCCC Programmatic Events Other HDFCCC Events
  • Sept 17: Diller Building Journal Club TBD
  • Sept 17: NO Breast Oncology Program seminars until October
  • Sept 18: NEW! Mount Zion RIP Lurie conf room 4pm
    "Hypoxia induces resistance to endocrine therapy" presented by Merce Padro Jove Post-doc, Denise Chan Lab
  • Sept 19: Cancer Center Seminar
    "Targeting Anti-Apoptotic MCL-1 in Malignancy" presented by Joseph Opferman, PhD, St. Jude Children's Research Hospital
  • Sept 27: Taste for the Cure: A Taste of Science
Conferences, Symposia, Retreats

Funding Opportunities

RAP Fall 2014 Cycle

E-submission deadline: Monday, September 22, 2014, 2 p.m.
The UCSF Resource Allocation Program (RAP) is now inviting applications for the Fall 2014 Cycle. RAP offers a single online application process for a wide variety of intramural grant offerings, which can be found online. Award notifications for grants reviewed by RAP review committees: January 2015. Sample RAP grants include:

RAP grants of interest include:

2015 Lurie Prize in Biomedical Sciences

The Foundation for the National Institutes of Health (FNIH) is accepting nominations for the 2015 Lurie Prize in Biomedical Sciences, an annual award recognizing outstanding achievement by a young scientist in biomedical research.
DEADLINE: October 14, 2014, 1:00 PM Eastern Daylight Time
Prize Amount: $100,000


Current Limited Submission Opportunities (Applications through LSO office)

  • Application Deadline October 31 :
    2015 Clinical Investigator Development Program
    The Center for Cancer Research (CCR) is pleased to announce an opportunity for physicians interested in dedicating their careers to clinical oncology research. Our Clinical Investigator Development Program will enable talented physician-scientists to develop clinical research projects within a vibrant, multidisciplinary research community of more than 250 talented CCR intramural scientists conducting cutting-edge research on the campuses of the National Institutes of Health in Bethesda and Frederick, Maryland.
    > Read more here



UCSF-HDFCCC Karen Gehrman, Communications
415.353.4471 (voice) | communications@cc.ucsf.edu

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and privileged information for the use of the designated recipient/s named above. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient/s is prohibited.